Recent News

• 06.09.2026 - Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
• 06.02.2026 - Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
• 05.20.2026 - Trump’s psychedelic drug order boosts investor interest with promise of faster reviews [Reuters]
• 05.19.2026 - New antidepressants: Tackling treatment resistant depression [LaBiotech]
• 05.19.2026 - Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
• 05.15.2026 - Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

Recent Filings

• 06.09.2026 - EX-99.1 EX-99.1
• 06.09.2026 - 8-K Current report
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities